Artha-G, Mono-Gesic, Salflex, Salsitab
Classifications: analgesic (salicylate); nonsteroidal antiinflammatory drug (nsaid); Therapeutic: nsaid, analgesic; disease-modifying antirheumatic drug (dmard)
Pregnancy Category: C
500 mg, 750 mg tablets
Actions similar to those of other salicylates. Clinical studies suggest that salsalate does not produce significant gastric
irritation, and it has not been associated with reactions causing asthmatic attacks in susceptible individuals. Unlike aspirin,
it does not appear to inhibit platelet aggregation. Its antiinflammatory and analgesic activity may be mediated through
inhibition of the prostaglandin synthetase enzyme complex.
Has analgesic, antiinflammatory, and antirheumatic effects.
Symptomatic treatment, rheumatoid arthritis, osteoarthritis, and related rheumatic disorders.
Hypersensitivity to salicylates or NSAIDs, especially patients with history of asthma, nasal polyposis, or chronic urticaria;
chronic renal insufficiency; peptic ulcer; children <12 y; hemophilia; chickenpox, influenza, tinnitus; pregnancy (category
Liver function impairment; older adults; lactation.
Route & Dosage
Adult: PO 3253000 mg/d in divided doses (max: 4 g/d)
- Give with a full glass of water or food or milk to reduce GI adverse effects.
Adverse Effects (≥1%)GI:
Nausea, dyspepsia, heartburn, vomiting, diarrhea, risk of GI bleed. Special Senses:
Tinnitus, hearing loss (reversible). Body as a Whole:
Vertigo, flushing, headache, confusion, hyperventilation, sweating. CNS:
Diagnostic Test Interference
False-negative results for Clinistix; false-positives for Clinitest.
InteractionsDrug: Aminosalicylic acid
increases risk of salicylate toxicity
. Ammonium chloride
and other acidifying agents
elimination and increase risk of salicylate toxicity
increase risk of bleeding. oral hypoglycemic agents
increase hypoglycemic activity with salsalate doses >2 g/d. carbonic anhydrase inhibitors
enhance salicylate toxicity
add to ulcerogenic effects. Methotrexate toxicity
is increased. Low doses of salicylates may antagonize uricosuric effects of probenecid
and sulfinpyrazone. Herbal: Feverfew, garlic, ginger, ginkgo
may increase bleeding potential.
Readily absorbed from small intestine. Peak:
1.54 h. Metabolism:
Hydrolyzed in liver, GI mucosa
, whole blood, and other tissues. Elimination:
In urine. Half-Life:
Assessment & Drug Effects
- Symptom relief is gradual (may require 34 d to establish steady-state salicylate level).
- Monitor for adverse GI effects, especially in patient with a history of peptic ulcer disease.
Patient & Family Education
- Do not to take another salicylate (e.g., aspirin) while on salsalate therapy.
- Monitor blood glucose for loss of glycemic control in diabetes; drug may induce hypoglycemia when used with sulfonylureas.
- Report tinnitus, hearing loss, vertigo, rash, or nausea.